ApiJect Systems America has secured a $138M award from the U.S. Air Force to support two projects aimed at increasing the manufacturing capacity for blow-fill-seal injection devices as part of COVID-19 response efforts.
The Stamford, Conn.-based public benefit corporation will aim to grow the number of domestically produced BFS syringes through “Project Jumpstart” and “Project Rapid,” the Department of Defense said Monday.
Work under the sole-source award will take place across the U.S. through May 8, 2022.
The service branch intends to obligate $69M upon issuance of the undefinitized contract action and provide the remaining funds once the contract is definitized.
ApiJect also recently partnered with the Department of Health and Human Services to establish the RAPID Consortium to supply prefilled syringes to the U.S. Strategic National Stockpile for public health emergency use.